Related Experiment Video

Updated: May 9, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications

Alexios S Strimpakos1, Kostas N Syrigos, Muhammad Wasif Saif

  • 1Division of Oncology, Second Department of Internal Medicine, Attikon University Hospital, Greece.

JOP : Journal of the Pancreas
|July 13, 2013
PubMed

Insights

Pharmacogenomics advances in pancreatic cancer offer personalized treatment. Biomarkers like hENT1 and SPARC expression may predict patient response to chemotherapy, guiding individualized medicine strategies.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Translational Research

Background:

  • Advanced pancreatic adenocarcinoma survival remains poor despite treatment advances.
  • A subset of patients benefits from specific therapies, with underlying reasons often unclear.
  • Pharmacogenomics is crucial for developing individualized medicine approaches.

Purpose of the Study:

  • To highlight significant pharmacogenomic developments from the 2013 American Society of Clinical Oncology Annual Meeting.
  • To discuss the potential of genetic markers in predicting treatment response for pancreatic cancer patients.
  • To explore the feasibility of gene expression profiling for guiding cytotoxic therapy selection.

Main Methods:

  • Review of key pharmacogenomic abstracts from the 2013 ASCO Annual Meeting.
  • Analysis of the predictive role of human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine/5-fluorouracil response.
  • Evaluation of SPARC expression's predictive value in adjuvant gemcitabine treatment (CONCO-001 study).
  • Assessment of gene expression profiling for selecting cytotoxic treatments.

Main Results:

  • hENT1 expression may predict benefit from gemcitabine or 5-fluorouracil in the adjuvant setting.
  • High SPARC stroma and cytoplasmic expression negatively predicted outcomes in patients receiving adjuvant gemcitabine.
  • Gene expression profiling for treatment selection was demonstrated as feasible and potentially improves efficacy and predicts resistance.

Conclusions:

  • Pharmacogenomic markers like hENT1 show promise for clinical application in pancreatic cancer treatment selection.
  • SPARC expression serves as a negative predictive marker for adjuvant gemcitabine therapy.
  • Gene expression profiling represents a future strategy for personalized cytotoxic treatment in pancreatic cancer.

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...